TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00890500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30mg/m2/day IV x 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30mg/m2/day IV x 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 100 mg/m2/day IV x 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 100 mg/m2/day IV x 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithymocyte Globulin
Description: 1mg/kg/day x 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithymocyte Globulin
Description: 1mg/kg/day x 4 days
Study: NCT02498158

Intervention type: DEVICE
Intervention: MRI scans
Description: 20 subject (10 tolerant and 10 intolerant to heat) will undergo MRI scans (GE healthcare manufacturer) as follows:~1. anatomical scan according to standard protocol~2. functional scan according to the standard protocol of rest-state fMRI.~scans of 10 healthy subjects will be taken from existing scans at the imaging department.
Study: NCT04628442

Intervention type: PROCEDURE
Intervention: Sinonasal Debridement Procedure
Description: This is a medical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.

Intervention type: PROCEDURE
Intervention: Nasal Polyp Removal
Description: This is a surgical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.

Intervention type: PROCEDURE
Intervention: Biopsy
Description: A biopsy is optional and will remove a sample of inferior turbinate tissue from the nasal passage. It will be performed during a nasal polyp removal surgery already scheduled for patient care.
Study: NCT03206554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Large volume local anaesthetic intraarticularly
Study: NCT01966575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progestin
Description: The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
Study: NCT04520763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5min respiratory muscle exercises
Description: 5 min of hyperpnea at a target intensity of 60-80% MVV 15-30min after ingestion of 75g of glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15min respiratory muscle exercises
Description: 5 min of hyperpnea at a target intensity of 60-70% MVV 15-30min after ingestion of 75g of glucose
Study: NCT03161938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: intravenous
Study: NCT03834129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Two administrations, before anesthesia and during surgery, by intravenous infusion of dexmedetomidine 1 μg/kg in 250 ml of physiological serum for 30 minutes
Study: NCT03206554

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: sham injection
Study: NCT03834129

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride 0.9%
Description: Two administrations, before anesthesia and during surgery, by intravenous infusion of 250 ml of physiological serum for 30 minutes
Study: NCT03476785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: Subjects will perform high intensity aerobic exercise in addition to moderate intensity sessions 4-5 times per week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Yoga
Description: Subjects will perform strength and flexibility exercises.
Study: NCT00435799

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal cross-linking (CCL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin/dextran eyedrops

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV-X system
Study: NCT03163953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TPAG with long break
Description: PA coaching based on Thai Physical Activity Guideline (TPAG) and long break or break 15 minutes for every 2 hours (TPAG with LB)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TPAG with short break
Description: PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention
Study: NCT04136496

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Black-Eye Ink
Description: There are two proposed studies utilizing the Ink during differing timepoints.Both will identify patients with breast cancer, with a biopsied metastatic axillary lymph node(LN) with a tissue marker clip placed, as is current practice. In Study A, 0.5mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy. In Study B, 0.5mL of Black Eye Ink will be placed before neoadjuvant therapy. In both studies, the LN containing the tissue marker clip will be the one to have the radioactive seed and Ink inserted. The seed will still be inserted, in the event the dye is not well-visualized. In both studies, the surgeon will attempt to find the LN by direct visualization and then confirm the appropriate LN has been removed by using the Gamma probe and intra-operative radiographs. If the seed is not within the tattooed node, the LN containing the seed will also be removed. All lymph nodes injected with Ink will be removed by the surgeon;no Ink-injected node remains in body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Black-Eye Ink
Description: There are two proposed studies utilizing the Ink during differing timepoints.Both will identify patients with breast cancer, with a biopsied metastatic axillary lymph node(LN) with a tissue marker clip placed, as is current practice. In Study A, 0.5mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy. In Study B, 0.5mL of Black Eye Ink will be placed before neoadjuvant therapy. In both studies, the LN containing the tissue marker clip will be the one to have the radioactive seed and Ink inserted. The seed will still be inserted, in the event the dye is not well-visualized. In both studies, the surgeon will attempt to find the LN by direct visualization and then confirm the appropriate LN has been removed by using the Gamma probe and intra-operative radiographs. If the seed is not within the tattooed node, the LN containing the seed will also be removed. All lymph nodes injected with Ink will be removed by the surgeon;no Ink-injected node remains in body.
Study: NCT06552390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: HRN4HTx is a phase 1 rehabilitation intervention protocol for post-heart transplant focused on the physical exercise component, and an educational plan regarding risk factors and safety criteria. The intervention protocol and its assessments are implemented by the team's rehabilitation nurses, always safeguarding the protective isolation required for these patients. The physical training protocol is divided into five stages of progressive levels of intervention. The protocol was defined following FITT parameters, international recommendations, and an integrated teaching program aimed at the therapeutic regimen exercise area. The frequency of intervention sessions is 7 days a week, twice a day (average of 13 sessions per week) throughout the hospitalization.~The intensity was defined according to Borg's modified scale of subjective perception of exertion (SPE), which must be maintained at less than 5.
Study: NCT00890500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: GVHD Prophylaxis: Target range 3-12 ng/ml
Study: NCT01045655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOMCare
Description: 8 sessions of brief interpersonal psychotherapy or medication management; maintenance sessions through 12 months postpartum.
Study: NCT02560519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin solution
Description: Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.~During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy.The volume replacement therapy is not determined but will be based on the clinical decision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringers acetate solution
Description: The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.~During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not determined but will be based on the clinical decision.
Study: NCT02076555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education - Diabetes and Social Issues
Description: Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Social Issues was created. The module covers specific and detailed aspects of the topic social issues such as driver licence, hypoglycemia when driving, and the pass for severly handicapped persons. With this module, a more comprehensive education of patients with specific interest is possible.
Study: NCT03957109

Intervention type: PROCEDURE
Group type: OTHER
Intervention: general anesthesia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: general anesthesia
Study: NCT02594475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography
Description: 1. Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.~2. Selective bile duct cannulation is performed using wire-guided cannulation.~3. In case of difficult cannulation, precut is performed using a needle-knife.~4. After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography
Description: 1. Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.~2. Selective bile duct cannulation is performed using wire-guided cannulation.~3. In case of difficult cannulation, precut is performed using a needle-knife.~4. After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed.
Study: NCT02172521

Intervention type: DRUG
Intervention: Tiotropium bromide
Description: Tiotropium bromide18 micrograms by oral inhalation (1 x daily) with the HandiHaler®
Study: NCT02662777

Intervention type: DEVICE
Intervention: Eso-SPONGE® vacuum treatment
Study: NCT04527354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid
Description: Participants will receive Treamid 50 mg once a day during 4 weeks
Study: NCT03884855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical Cardiac Rehabilitation
Description: Patients benefit from classical cardiac rehabilitation during 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Karate rehabilitation
Description: Patients benefit from cardiac rehabilitation with traditional karate during 3 months. Patients will have four 60-minute group sessions four times a week, during which they will have 45-minute individual exercises and 15-minute pairs of exercises. The course of the sessions has been protocolised.
Study: NCT01064804

Intervention type: DRUG
Intervention: PF-04191834
Description: PF-04191834. 100mg Immediate Release Tablets or oral suspension
Study: NCT02466048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Fusion
Description: Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Fusion
Description: Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurgiFill™
Description: SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting. SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
Study: NCT00525850

Intervention type: OTHER
Group type: OTHER
Intervention: high fat diet
Description: high saturated fat no starch diet

Intervention type: OTHER
Group type: OTHER
Intervention: low saturated fat diet
Description: low calorie low saturated fat low trans fat high fiber diet
Study: NCT01596504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: solution for injection self-administered with a pen-like injector (OptiClik®).~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Doses to be adjusted to maintain a fasting self-measured plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Doses to be adjusted to maintain a fasting self-measured plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Doses to be adjusted to maintain a fasting self-measured plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: If previously taken metformin to be continued at stable dose throughout the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: If previously taken metformin to be continued at stable dose throughout the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: If previously taken metformin to be continued at stable dose throughout the study
Study: NCT00395018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: Tablets, Oral, 1 mg, once daily, up to 72 weeks
Study: NCT04534712

Intervention type: DIAGNOSTIC_TEST
Intervention: LYMPHOCYTE MONOCYTE RATIO
Description: Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.

Intervention type: DIAGNOSTIC_TEST
Intervention: LYMPHOCYTE MONOCYTE RATIO
Description: Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
Study: NCT03617406

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Volume Challenge
Description: Addition volume challenge with passive leg raising method in LDDSE as well as administration of normal saline and dobutamine during TEE
Study: NCT04635488

Intervention type: PROCEDURE
Intervention: lateral lymph node dissection
Description: All participted would receive lateral lymph node dissection for rectal cancer.

Intervention type: PROCEDURE
Intervention: lateral lymph node dissection
Description: All participted would receive lateral lymph node dissection for rectal cancer.
Study: NCT02010619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy
Study: NCT04330469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Description: Treatment will be performed by a periodontist.~1. Intensive removal of subgingival and supragingival calculus and plaque biofilm by scaling, root-planing and polishing. The procedures will be carried out with the use of hand scalers and a piezoelectric ultrasonic scaler with universal tips. Disclosing solution will be used to visualize the plaque for the clinician.~2. One to four sessions of subgingival scaling and root planing by quadrant, under local anesthesia as may be deemed necessary during the study period.~3. Subgingival irrigation using an antiseptic mouth rinse (chlorhexidine 0.12%).~4. Polishing of the coronal and radicular surfaces of the teeth.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Oral hygiene advice
Description: Oral hygiene advised by Periodontist
Study: NCT00890500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: GVHD Prophylaxis: Target range 3-12 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: GVHD Prophylaxis: Target range 5-10 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: GVHD Prophylaxis: Target range 5-10 ng/ml
Study: NCT03186547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A Injection
Description: adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Lip Repositioning Surgery
Description: the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
Study: NCT00765492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8529
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT00866554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administration of a LHRH agonist and Bicalutamide
Description: 3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Bicalutamide, Dutasteride and Tamoxifen
Description: Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered.
Study: NCT00107835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Description: S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine was applied topically. The study drug remained on the treatment area for 20-30 minutes for minor dermal procedures and 60 minutes for major dermal procedures
Study: NCT00909363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promacta
Description: WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests.~they will also have diagnostic blood testing prior to initiating treatment
Study: NCT04645940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole
Description: fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole
Description: fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29.
Study: NCT00715091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclophenac
Description: continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclophenac
Description: treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
Study: NCT04580849

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telerehabilitation with dance
Description: Dance classes will be provided through a online platform. Each class will last 60 minutes, twice a week, during 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation with dance
Description: Dance classes will be provided through a online platform. Each class will last 60 minutes, twice a week, during 8 weeks.
Study: NCT02288494

Intervention type: OTHER
Intervention: stewart approach
Description: Prospective study, for ICU patient with severe hypoalbuminemia \< 20g/L, determining biological parameters from Stewart approach for acid base disorders (pH, SIDe, SIDa, SIG, Atot, PaCO2) before, and at 1hour, 2hours and 24 hours after a 200mL 20% human al Clinical parameters (respiratory, haemodynamic, neurologic) were also collected at the same times.